August 24, 2024 (Sat. Only)
Managing Metabolic Disorders Pharmacy CE Conference
(6 hrs. CPE)

August 24, 2024 (Sat. Only)
Managing Metabolic Disorders Pharmacy CE Conference
(6 hrs. CPE)

$150.00

ACCREDITATION

iCARE Pharmacy Services, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an ACPE application-based* and knowledge-based activity. Participants may receive up to 6 hours of CPE credit by attending sessions and successfully completing the continuing pharmacy education (CPE) activity evaluation.

iCARE Pharmacy Services, Inc. is approved by the Florida Board of Pharmacy as a provider of continuing pharmacy education.

DISCLOSURES

Speakers have no relevant conflict of interests nor financial relationships.  All persons in a position to control the content of this activity have declared that no conflict of interest exists for this activity.

TARGET AUDIENCE

Pharmacists and Pharmacy Technicians of all practice backgrounds.

CANCELLATION POLICY
Participants must submit cancellations in writing. Participants will receive a credit for a future CPE program.

ZOOM WEBINAR INFORMATION
Participants may join via any electronic device. Be sure to have downloaded the ZOOM software in advance to avoid any delays. You will be able to see the speakers and their presentations. You will be able to respond to speaker learning assessments via the CHAT Feature and ask questions via the Q&A Feature.

Description

Saturday, August 24, 2024

Beyond Insulin: Advancements in Type 1 Diabetes Care                                  

8:00-9:30am Consultant/General

Jasmine B. R. Cutler, Pharm.D., CPh, Assistant Professor, Dept of Pharmacotherapeutics and Clinical Research, USF Health Taneja College of Pharmacy, University of South Florida

Upon completion of this activity, pharmacists will be able to: Discuss the pathophysiology, clinical presentation, and risk factors of diabetes; Explain the differences between Type 1 and Type 2 diabetes; Discuss available treatment options for Type 1 diabetes; Demonstrate proper insulin administration; Discuss blood glucose monitoring and management of hypoglycemia and hyperglycemia; Introduce emerging therapies and technologies used in the treatment of diabetes, specifically Type 1 diabetes; Discuss the financial implications of Type 1 diabetes and available resources to address patient concerns and questions; Highlight lifestyle management of Type 1 diabetes; Apply learned concepts about Type 1 diabetes to a patient case.

UAN: 0675-0000-24-021-L01-P*

 

Rethinking and Reframing Obesity Management               9:30-11:00am Consultant/General

Marile Santamarina, PharmD, CPh, CDE, CPT, Sr. Medical Science Liaison, Immunology, Fresenius Kabi USA

Upon completion of this activity, pharmacists will be able to: Identify obesity as a chronic disease; Review the challenges of anti-obesity drug development; Discuss clinical practice guidelines for the management of obesity.

UAN: 0675-0000-24-022-L01-P

 

A New Era in the Management of Type 2 Diabetes              

11:15-12:45pm Consultant/General

Marile Santamarina, PharmD, CPh, CDE, CPT, Sr. Medical Science Liaison, Immunology, Fresenius Kabi USA

Upon completion of this activity, pharmacists will be able to: Provide an overview of complex pathophysiology of Type 2 Diabetes (T2D); Review change progression in the American Diabetes Association Clinical Practice Guidelines from 2018 through 2024; Discuss the clinical positioning of newer drug classes in the management of type 2 diabetes; Recommendation clinical decisions using patient practice cases.

UAN: 0675-0000-24-023-L01-P

 

Critical Importance of Lowering LDL-C and Applying Lipid Guidelines

12:45-2:15pm Consultant/General

Ana M. Alvarez, PharmD, CPh, LCC, Senior Medical Science Liaison, Cardiovascular, Novo Nordisk, Inc

Upon completion of this activity, pharmacists will be able to: Correlate the relationship between plasma lipids and coronary heart disease; Defend the rationale for drug selection among various classes of drugs used to reduce cholesterol; Integrate guideline-recommended strategies for lowering LDL-C in primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD); Develop evidence-based treatment plan for patients with elevated LDL-C.

UAN: 0675-0000-24-024-L01-P*